Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have heart failure where the heart's pumping function is weakened (specifically, the heart pumps out less than 50% of its blood with each beat, as measured by an ultrasound of the heart), and who have a leaky mitral valve (a valve in the heart) that is considered significant
- People whose heart failure has already been treated as thoroughly as possible with medications and any relevant heart devices, following medical guidelines
- People who are scheduled to have a minimally invasive procedure to repair the leaky mitral valve using an FDA-approved device called MitraClip
Who may not be able to join:
- People who are having a heart artery procedure (called PCI) done at the same time as the mitral valve repair procedure
- People who were born with a structural heart condition (congenital heart disease)
- People whose heart failure is at the most advanced and severe stage (Stage D)
- People with atrial fibrillation (an irregular heart rhythm) that is not under control
- People who are pregnant
- People who have more than a moderate leak in the tricuspid valve (another valve in the heart)
- People who have more than a moderate leak or narrowing in the aortic valve (another valve in the heart)
- People who have a medical reason they cannot undergo a cardiac MRI scan, or who are otherwise unable to have one (confirm with trial site)
- People who have previously had repair or replacement surgery on their mitral valve
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: João Cavalcante, MD, Minneapolis Heart Institute Foundation
Phone: 612-863-3900
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Estimate the association between LV myocardial fibrosis by CMR late gadolinium enhancement imaging before TEER with LV reverse remodeling.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.